GSK sells off partial stake in Haleon for $1.2B

Wirestock/iStock Editorial via Getty Images GSK ( NYSE: GSK ) said on Tuesday it has agreed to sell 300M shares of Haleon ( NYSE: HLN ) for gross proceeds of approximately £978M, or $1.2B. The British drugmaker's announcement came after a report earlier in the day. The 300M shares represent a 3.2% stake in consumer health giant Haleon.

GSK now holds a 4.2% interest in Haleon, down from 12.94% at the time of the latter's demerger in 2022. GSK has been selling off its stake in Haleon since the demerger. It disposed 510M shares in two tranches in 2023, bringing its stake down to 7.4% at the end of the year. This latest sale marks the third one in less than a year.

Haleon ( HLN ) was formed in 2019 by merging the consumer health businesses of GSK and Pfizer ( PFE ). Pfizer holds a 32% stake in Haleon, according to GSK. More on GSK, Haleon plc, etc. GSK plc (GSK) 42nd Annual JP Morgan Healthcare Conference (Transcript) Haleon plc 2023 Q3 Results Earnings Call Presentation AbbVie Vs.

GSK: Dual Dominance In Pharma First RSV shots, groundbreaking gene therapy among 2024 drugs to watch.